Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Oct. 26, 2023 -- Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and...

Related Keywords

,James Breitmeyer ,Richard Vincent ,Corey Davis ,Nasdaq ,Drug Administration ,Oncternal Therapeutics Inc ,Globenewswire Inc ,Fast Track ,Receptor Tyrosine Kinase Like Orphan ,Markets ,